SKIP TO CONTENT
Johns Hopkins
  • Home
  • About
  • News
  • Contact
  • Login

    • FDA Approves Drug Targeting Johns Hopkins-Discovered Brain Cancer Gene Mutation

    FDA Approves Drug Targeting Johns Hopkins-Discovered Brain Cancer Gene Mutation

    A new drug for treatment of a type of brain cancer, called IDH-mutant low-grade glioma, was approved Aug. 6 by the U.S. Food and Drug Administration (FDA). The promising new drug stems from a 2008 genetic discovery made at the Johns Hopkins Kimmel Cancer Center.

    LEARN MORE
    SEE ALL NEWS
    Recent Posts
    Study Suggests a Healthy Diet May Help Keep Low Grade Prostate Cancer From Progressing to More Dangerous States During Active Surveillance Experimental Cancer Drug Eliminates Bone Metastases Caused by Breast Cancer in Lab Models Johns Hopkins Joins Cancer AI Alliance AI ‘Liquid Biopsies’ Using Cell-Free DNA, Protein Biomarkers, Could Aid Early Detection of Ovarian Cancer A Common Culprit Drives Prostate Cancer Progression Immunotherapy Before and After Lung Cancer Surgery Reduces Death Risk, Disease Recurrence Age-Related Changes in Male Fibroblasts Increase Treatment-Resistant Melanoma Scientists Identify Potential New Immune System Target to Head Off the Spread of Breast Cancer Cells Johns Hopkins Researchers Identify Key Markers in Pancreatic Cancer Progression Using a New Analysis Pipeline
    Johns Hopkins

    2024 © The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.
    Terms of Use Privacy Statement

    LinkedIn
    Back to top